Overview

A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention

Status:
Completed

Trial end date:
2007-07-01

Target enrollment:

Participant gender:

Summary

The sponsors of this investigational drug are developing prasugrel (also known as CS-747) as a possible treatment for patients with acute coronary syndrome (heart attack or chest pain) who need, or are expected to need, a percutaneous coronary intervention (PCI; also called a balloon angioplasty). Prasugrel was compared with Clopidogrel to determine which drug is better at reducing deaths, future heart attacks, or stroke.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Collaborators:

Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.

Treatments:

Clopidogrel
Prasugrel Hydrochloride
Ticlopidine